<- Go Home

Haleon plc

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

Market Cap

GBP 29.7B

Volume

23.1M

Cash and Equivalents

GBP 1.3B

EBITDA

GBP 2.7B

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

GBP 7.1B

Profit Margin

64.77%

52 Week High

GBP 4.20

52 Week Low

GBP 2.74

Dividend

2.13%

Price / Book Value

1.81

Price / Earnings

18.05

Price / Tangible Book Value

-3.24

Enterprise Value

GBP 37.0B

Enterprise Value / EBITDA

13.24

Operating Income

GBP 2.5B

Return on Equity

10.27%

Return on Assets

4.67

Cash and Short Term Investments

GBP 1.4B

Debt

GBP 8.6B

Equity

GBP 16.5B

Revenue

GBP 11.0B

Unlevered FCF

GBP 1.6B

Sector

Pharmaceuticals

Category

N/A

Company Stock Pitches